Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
L Xiong, R Li, J Sun, Y Lou, W Zhang, H Bai… - The …, 2019 - academic.oup.com
Abstract Lessons Learned The findings of this prospective, single‐arm, phase II study
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.
L Xiong, R Li, J Sun, Y Lou, W Zhang, H Bai… - The …, 2018 - europepmc.org
Background Information on epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) as neoadjuvant therapy in non-small cell lung cancer (NSCLC) is scarce …
inhibitors (TKIs) as neoadjuvant therapy in non-small cell lung cancer (NSCLC) is scarce …
[HTML][HTML] Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
L Xiong, R Li, J Sun, Y Lou, W Zhang, H Bai… - The …, 2019 - ncbi.nlm.nih.gov
Background. Information on epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) as neoadjuvant therapy in non-small cell lung cancer (NSCLC) is scarce …
inhibitors (TKIs) as neoadjuvant therapy in non-small cell lung cancer (NSCLC) is scarce …
[PDF][PDF] Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
L Xiong, R Li, J Sun, Y Lou, W Zhang, H Bai… - The …, 2019 - Wiley Online Library
Abstract Lessons Learned The findings of this prospective, single‐arm, phase II study
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study.
L Xiong, R Li, J Sun, Y Lou, W Zhang, H Bai… - …, 2019 - search.ebscohost.com
Background. Information on epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) as neoadjuvant therapy in non-small cell lung cancer (NSCLC) is scarce …
inhibitors (TKIs) as neoadjuvant therapy in non-small cell lung cancer (NSCLC) is scarce …
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
L Xiong, R Li, J Sun, Y Lou, W Zhang, H Bai, H Wang… - The Oncologist, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Lessons Learned</jats: title><
jats: p> The findings of this prospective, single-arm, phase II study showed that neoadjuvant …
jats: p> The findings of this prospective, single-arm, phase II study showed that neoadjuvant …
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
L Xiong, R Li, J Sun, Y Lou, W Zhang, H Bai… - The …, 2019 - pubmed.ncbi.nlm.nih.gov
Lessons learned The findings of this prospective, single-arm, phase II study showed that
neoadjuvant erlotinib was well tolerated and might improve the radical resection rate in …
neoadjuvant erlotinib was well tolerated and might improve the radical resection rate in …
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.
L Xiong, R Li, J Sun, Y Lou, W Zhang, H Bai… - The …, 2018 - europepmc.org
Background Information on epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) as neoadjuvant therapy in non-small cell lung cancer (NSCLC) is scarce …
inhibitors (TKIs) as neoadjuvant therapy in non-small cell lung cancer (NSCLC) is scarce …